Found 46 results
Author Keyword Title Type [ Year(Asc)]
Filters: Keyword is Paclitaxel  [Clear All Filters]
A. M. Poveda, Selle, F., Hilpert, F., Reuss, A., Savarese, A., Vergote, I. B., Witteveen, P., Bamias, A., Scotto, N., Mitchell, L., and Pujade-Lauraine, E., Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial., J Clin Oncol, vol. 33, no. 32, p. 3838, 2015.
R. T. Penson, Huang, H. Q., Wenzel, L. B., Monk, B. J., Stockman, S., Long, H. J., Ramondetta, L. M., Landrum, L. M., Oaknin, A., Reid, T. J. A., Leitao, M. M., Method, M., Michael, H., and Tewari, K. S., Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240)., Lancet Oncol, vol. 16, no. 3, pp. 301-11, 2015.
S. Mahner, Meier, W., du Bois, A., Brown, C., Lorusso, D., Dell'Anna, T., Cretin, J., Havsteen, H., Bessette, P., Zeimet, A. G., Vergote, I. B., Vasey, P. A., Pujade-Lauraine, E., Gladieff, L., and Ferrero, A., Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial., Eur J Cancer, vol. 51, no. 3, pp. 352-8, 2015.
C. Khoon Lee, Lord, S., Grunewald, T., Gebski, V., Hardy-Bessard, A. - C., Sehouli, J., Woie, K., Heywood, M., Schauer, C., Vergote, I. B., Scambia, G., Ferrero, A., Harter, P., Pujade-Lauraine, E., and Friedlander, M. Leonard, Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: analysis of the CALYPSO trial., Gynecol Oncol, vol. 136, no. 1, pp. 18-24, 2015.
A. M. Oza, Cook, A. D., Pfisterer, J., Embleton, A. C., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G. B., Carey, M. S., Beale, P., Cervantes, A., Park-Simon, T. - W., Rustin, G. J. S., Joly, F., Mirza, M. R., Plante, M., Quinn, M., Poveda, A. M., Jayson, G. C., Stark, D., Swart, A. Marie, Farrelly, L., Kaplan, R. S., Parmar, M. K. B., and Perren, T. J., Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial., Lancet Oncol, vol. 16, no. 8, p. 936, 2015.
E. Pujade-Lauraine, Hilpert, F., Weber, B., Reuss, A., Poveda, A. M., Kristensen, G. B., Sorio, R., Vergote, I. B., Witteveen, P., Bamias, A., Pereira, D., Wimberger, P., Oaknin, A., Mirza, M. Raza, Follana, P., Bollag, D., and Ray-Coquard, I., Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial., J Clin Oncol, vol. 32, no. 13, p. 1308, 2014.
K. S. Tewari, Sill, M. W., Long, H. J., Penson, R. T., Huang, H., Ramondetta, L. M., Landrum, L. M., Oaknin, A., Reid, T. J., Leitao, M. M., Michael, H. E., and Monk, B. J., Improved survival with bevacizumab in advanced cervical cancer., N Engl J Med, vol. 370, no. 8, pp. 734-43, 2014.
M. R. Stockler, Hilpert, F., Friedlander, M. Leonard, King, M. Trudy, Wenzel, L. B., Lee, C. Khoon, Joly, F., de Gregorio, N., Arranz, J. Angel, Mirza, M. Raza, Sorio, R., Freudensprung, U., Sneller, V., Hales, G., and Pujade-Lauraine, E., Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer., J Clin Oncol, vol. 32, no. 13, p. 1316, 2014.
K. Harano, Terauchi, F., Katsumata, N., Takahashi, F., Yasuda, M., Takakura, S., Takano, M., Yamamoto, Y., and Sugiyama, T., Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: JGOG Trial (JGOG3016)., Ann Oncol, vol. 25, no. 1, pp. 251-7, 2014.
J. Alexandre, Brown, C., Coeffic, D., Raban, N., Pfisterer, J., Maenpaa, J. U., Chalchal, H., Fitzharris, B., Volgger, B., Vergote, I. B., Pisano, C., Ferrero, A., and Pujade-Lauraine, E., CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial., Br J Cancer, vol. 106, no. 4, p. 637, 2012.
L. Gladieff, Ferrero, A., De Rauglaudre, G., Brown, C., Vasey, P. A., Reinthaller, A., Pujade-Lauraine, E., Reed, N. Simon, Lorusso, D., Siena, S., Helland, H., Elit, L., and Mahner, S., Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial., Ann Oncol, vol. 23, no. 5, pp. 1185-9, 2012.
U. Wagner, Marth, C., Largillier, R., Kaern, J., Brown, C., Heywood, M., Bonaventura, T., Vergote, I. B., Piccirillo, M. C., Fossati, R., Gebski, V., and Lauraine, E. P., Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients., Br J Cancer, vol. 107, no. 4, p. 591, 2012.
K. Lindemann, Christensen, R. D., Vergote, I. B., Stuart, G. C. E., Izquierdo, M. A., Kærn, J., Havsteen, H., Eisenhauer, E., Ridderheim, M., Lopez, A. B., Hirte, H., Åvall-Lundqvist, E., Vrdoljak, E., Green, J. A., and Kristensen, G. B., First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)--a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG., Ann Oncol, vol. 23, no. 10, pp. 2613-9, 2012.
M. Brundage, Gropp, M., Mefti, F., Mann, K., Lund, B., Gebski, V., Wolfram, G., Reed, N. Simon, Pignata, S., Ferrero, A., Brown, C., Eisenhauer, E., and Pujade-Lauraine, E., Health-related quality of life in recurrent platinum-sensitive ovarian cancer--results from the CALYPSO trial., Ann Oncol, vol. 23, no. 8, p. 2027, 2012.
F. Joly, Ray-Coquard, I., Fabbro, M., Donoghoe, M., Boman, K., Sugimoto, A., Vaughan, M., Reinthaller, A., Vergote, I. B., Ferrandina, G., Dell'Anna, T., Huober, J., and Pujade-Lauraine, E., Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial., Gynecol Oncol, vol. 122, no. 2, p. 232, 2011.
S. Kumagai, Sugiyama, T., Shoji, T., Michimae, H., Katsumata, N., Aoki, D., Terauchi, F., Jobo, T., Ochiai, K., and Yasuda, M., Does severe anemia caused by dose-dense paclitaxel-Carboplatin combination therapy have an effect on the survival of patients with epithelial ovarian cancer? Retrospective analysis of the Japanese gynecologic oncology group 3016 trial., Int J Gynecol Cancer, vol. 21, no. 9, pp. 1585-91, 2011.
F. A. Raja, Griffin, C. L., Qian, W., Hirte, H., Parmar, M. K. B., Swart, A. Marie, and Ledermann, J. A., Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer., Br J Cancer, vol. 105, no. 7, pp. 884-9, 2011.
J. - E. Kurtz, Kaminsky, M. C., Floquet, A., Veillard, A. S., Kimmig, R., Dorum, A., Elit, L., Buck, M., Petru, E., Reed, N. Simon, Scambia, G., Varsellona, N., Brown, C., and Pujade-Lauraine, E., Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study., Ann Oncol, vol. 22, no. 11, p. 2423, 2011.
T. J. Perren, Swart, A. Marie, Pfisterer, J., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G. B., Carey, M. S., Beale, P., Cervantes, A., Kurzeder, C., du Bois, A., Sehouli, J., Kimmig, R., Stähle, A., Collinson, F., Essapen, S., Gourley, C., Lortholary, A., Selle, F., Mirza, M. R., Leminen, A., Plante, M., Stark, D., Qian, W., Parmar, M. K. B., and Oza, A. M., A phase 3 trial of bevacizumab in ovarian cancer., N Engl J Med, vol. 365, no. 26, p. 2496, 2011.
H. Nomura, Aoki, D., Takahashi, F., Katsumata, N., Watanabe, Y., Konishi, I., Jobo, T., Hatae, M., Hiura, M., and Yaegashi, N., Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: a Japanese Gynecologic Oncology Group study (JGOG2041)., Ann Oncol, vol. 22, no. 3, pp. 636-42, 2011.